If not treated, ATTRv-PN patients can lose sensation in their legs and feet. Credit: ljubaphoto via Getty Images. AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the ...

AstraZeneca’s Imfinzi is under regulatory review in China, Japan and other countries. Credit: © AstraZeneca 2025. AstraZeneca’s Imfinzi (durvalumab) plus ...

AstraZeneca and Daiichi Sankyo also recently won the FDA’s approval for another ADC they are working on together. Datroway, which also carries a topoisomerase I inhibitor but instead targets the TROP2 ...

March 3 (UPI) --Colombia President Gustavo Petro is calling ... Mastercard, Pfizer and AstraZeneca, that the world's second-largest economy is open for business amid a looming tariffs threat.

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the ...

Also Read: Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca’s Asthma Drug On Efficacy, Analysts Say Treatment with Tezspire significantly reduced nasal polyp severity: the Nasal ...

Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts across multiple therapeutic areas expected in 2025 ...

Tezspire targets the airway epithelium, the primary source of inflammation. Credit: Emily Frost / Shutterstock. Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with ...

In a heated competition among BTK inhibitor treatments for blood cancer, BeiGene’s third-to-market Brukinsa has for the first time surpassed AstraZeneca’s Calquence in quarterly sales.

AstraZeneca’s camizestrant is presently under evaluation in Phase III trials targeting HR-positive breast cancer. Credit: © AstraZeneca 2025. AstraZeneca has ...